Dsm-Firmenich Beats Estimates on Contract Wins
The Dutch-Swiss nutrition and beauty ingredients group reported third-quarter core profit slightly above market expectations.
Updated on Nov. 4, 2026 in Corporate Finance
Dsm-firmenich reported third-quarter core profit a touch above market expectations on Wednesday, citing more contract wins. The company also raised its full-year growth outlook to around 5%.
Why it matters
The results suggest demand for the company's ingredients held up through the quarter, with growth ahead of forecasts in its beauty business. Raising the full-year outlook signals management's confidence heading into the fourth quarter.
Quarterly adjusted EBITDA reached €482 million ($541.29 million), slightly above the €478 million company-provided consensus. Perfumery & Beauty like-for-like sales grew 8%, ahead of the 5.5% analysts expected.
The players
Dsm-firmenich
A Dutch-Swiss nutrition, health and beauty ingredients company formed by the merger of Royal DSM and Firmenich, supplying flavors, fragrances and nutritional ingredients to global consumer brands.
The details
Sales rose to €2.37 billion in the quarter, edging past the €2.36 billion consensus forecast. The company now forecasts full-year growth of around 5%, up from its previous 2-4% range.
Timeline
Wednesday, November 4, 2026: Dsm-firmenich reports third-quarter results and raises its growth outlook.
Market Landscape
The results reflect how the merged dsm-firmenich group, formed from Royal DSM and Firmenich, is performing as a combined supplier of beauty and nutrition ingredients. Beating consensus while adding contract wins points to competitive positioning against other large ingredient makers.
For investors holding dsm-firmenich shares, the raised growth outlook is the most direct signal from the report. Consumers of the group's downstream brands are not directly affected by the financial figures reported here.
The takeaway
Raised guidance after a beat is a useful signal to watch alongside the quarter's underlying sales growth. Investors should compare future updates against this 5% full-year forecast.
Further reading
Track more company earnings and deal coverage in Corporate Finance.
